优立新序贯疗法治疗急性下呼吸道细菌性感染的疗效  

TREATMENT OF ACUTE LOWER RESPIRETORY TRACT BACTERIAL INFECTION BY UNASYN IN SEQUENTIAL THERAPY

作　　者：王秋月[1] 田莉莉[1] 康健[1] 侯显明[1] 于润江[1] 

机构地区：[1]中国医科大学呼吸疾病研究所

出　　处：《中国新药杂志》1999年第1期33-35,共3页Chinese Journal of New Drugs

摘　　要：目的：评价优立新序贯疗法治疗急性下呼吸道细菌感染的疗效和安全性。方法：对３４例急性下呼吸道细菌感染患者，采用优立新３．０～４．５ｇ／ｄ，５～７ｄ静脉滴注，继之以１．５ｇ／ｄ，４～７ｄ，ｐｏ。结果：痊愈１０例（２９．４％），显效２１例（６１．８％），治愈率９１．２％，细菌消除率９３．３％，总疗程７～１４ｄ（平均１１．８ｄ），药物副作用较少（发生率２．９％）。结论：优立新序贯疗法治疗急性下呼吸道常见细菌性感染有效、安全。OBJECTIVE:To evaluate the efficacy and safety of Unasyn in treatment of acute lower respiratory tract bacterial infection(ALRTBI)by sequential therapy.METHODS:Thirty four patients with ALRTBI were treated with Unasyn iv drip in a regimen of 3.0～4.5 g/d for 5～7 d then with oral Unasyn in dose of 1.5 g/d for 4～7 d in sequence.RESULTS:An effective rate of 91.2% and a bacterial eradication rate of 93.3% were obtained with a tolerable side effect of 2.9%.CONCLUSION:Unasyn in sequential therapy is an effective and safe agent for treatment of ALRTBI.

关 键 词：优立新 细菌感染 下呼吸道感染 治疗 

分 类 号：R563.305[医药卫生—呼吸系统]